Prostaglandin E2 modulates IL-8 expression through formation of a multiprotein enhanceosome in human colonic epithelial cells

被引:19
作者
Srivastava, Vikas [1 ]
Dey, Indranil [1 ]
Leung, Pearl [1 ]
Chadee, Kris [1 ]
机构
[1] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Hlth Sci Ctr, Calgary, AB, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
CREB; Gene regulation; ICER; Inflammation; Promoter; EP4 PROSTANOID RECEPTORS; GENE-EXPRESSION; INTERLEUKIN-8; GENE; BINDING PROTEIN; INFLAMMATION; MICE; CREB; E-2; CYCLOOXYGENASE-2; TRANSCRIPTION;
D O I
10.1002/eji.201141965
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gastrointestinal inflammation is mediated by the pro-inflammatory mediators interleukin-8 (IL-8) and prostaglandin E2 (PGE2). PGE2 binding and coupling through EP2/4 receptor subtypes on colonic epithelial cells stimulates cyclic adenosine monophosphate (cAMP) and IL-8 production. Here we determined the mechanisms whereby PGE2 regu-lates IL-8 in Caco2 colonic epithelial cells and in cells over-expressing the EP2/4 receptors (EP2S/EP4S). PGE2 coupling through EP2 activated the transcription factor inducible cAMP early repressor (ICER), whereas coupling through EP4 receptors activated the cyclic AMP-responsive element-binding protein (CREB). Activation of CREB in Caco2/EP2S was protein kinase A (PKA) dependent, whereas in EP4S cells, activation of CREB occurred through the PKA and phosphatidylinositol 3-kinase pathways. Since ICER lacks the transactivation domain, it functions as a transcription repressor as opposed to CREB. PGE2 coupling through EP2/4 receptors can therefore acts in an opposing manner to either decrease (EP2) or promote IL-8 expression by recruiting CREB-binding protein (CBP) (EP4), which formed a multiprotein IL-8 enhanceosome. A novel half CRE (167CRE) and a composite NFAT1-AP1-like site in the IL-8 promoter participated in binding and complex formation as confirmed by mutagenesis and expression studies. These data unravel the mechanisms by which expression of IL-8 is controlled by different signalling pathways that are activated by PGE2 but acting through different EP receptors.
引用
收藏
页码:912 / 923
页数:12
相关论文
共 28 条
[1]   Prostanoid signal transduction and gene expression in the endothelium:: Role in cardiovascular diseases [J].
Alfranca, Arantzazu ;
Iniguez, Miguel A. ;
Fresno, Manuel ;
Redondo, Juan Miguel .
CARDIOVASCULAR RESEARCH, 2006, 70 (03) :446-456
[2]   CREB-binding protein and p300: molecular integrators of hematopoietic transcription [J].
Blobel, GA .
BLOOD, 2000, 95 (03) :745-755
[3]   Role of transcriptional repressor ICER in cyclic AMP-mediated attenuation of cytokine gene expression in human thymocytes [J].
Bodor, J ;
Habener, JF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9544-9551
[4]   PHOSPHORYLATED CREB BINDS SPECIFICALLY TO THE NUCLEAR-PROTEIN CBP [J].
CHRIVIA, JC ;
KWOK, RPS ;
LAMB, N ;
HAGIWARA, M ;
MONTMINY, MR ;
GOODMAN, RH .
NATURE, 1993, 365 (6449) :855-859
[5]  
COLEMAN RA, 1994, PHARMACOL REV, V46, P205
[6]   Prostanoids in human colonic mucosa:: Effects of inflammation on PGE2 receptor expression [J].
Cosme, R ;
Lublin, D ;
Takafuji, V ;
Lynch, K ;
Roche, JK .
HUMAN IMMUNOLOGY, 2000, 61 (07) :684-696
[7]   Prostaglandin E2 receptor distribution and function in the gastrointestinal tract [J].
Dey, I. ;
Lejeune, M. ;
Chadee, K. .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 149 (06) :611-623
[8]   Prostaglandin E2 couples through EP4 prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines [J].
Dey, I. ;
Giembycz, M. A. ;
Chadee, K. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 156 (03) :475-485
[9]   Transcriptional coactivators CBP and p300 cooperatively enhance HNF-1α-mediated expression of the albumin gene in hepatocytes [J].
Dohda, T ;
Kaneoka, H ;
Inayoshi, Y ;
Kamihira, M ;
Miyake, K ;
Iijima, S .
JOURNAL OF BIOCHEMISTRY, 2004, 136 (03) :313-319
[10]   Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2 [J].
Fujino, H ;
Salvi, S ;
Regan, JW .
MOLECULAR PHARMACOLOGY, 2005, 68 (01) :251-259